Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 0.41 |
| ▸ | PTPRC | P08575 | 2/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL192403 | 0.85 | MAOB (0.50) | LTA4HMEN1KMT2AALDH1A1 | |
| SCHEMBL9042229 | 0.84 | LMNA (0.46) | PTPN1PTPRCCA12CA1CA2 | |
| SCHEMBL4689225 | 0.84 | LMNA (0.46) | PTPN1PTPRCCA12CA1CA2 | |
| SCHEMBL3379309 | 0.82 | SMN1; SMN2 (0.41) | PTPN1PTPRCP2RX7CA12CA1 | |
| SCHEMBL3378133 | 0.79 | CA12 (0.41) | PTPN1CA12CA1CA2CA9 | |
| SCHEMBL2574959 | 0.76 | LTA4H (0.49) | LTA4HMEN1KMT2AALDH1A1 | |
| SCHEMBL4683877 | 0.75 | LTA4H (0.42) | PTPN1PTPRCLTA4HMEN1KMT2A | |
| SCHEMBL7048725 | 0.75 | CXCR2 (0.38) | CA12CA1CA2CA9 | |
| SCHEMBL1826015 | 0.74 | CA12 (0.39) | PTPN1P2RX7CA12CA1CA2 | |
| SCHEMBL1827566 | 0.74 | CA12 (0.39) | PTPN1P2RX7CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7427635-B2 | Substituted hydantoins | HOFFMANN-LA ROCHE INC. (US) | 2008-09-23 | — | — | US | disclosed |
| EP-1781649-B1 | SUBSTITUTED HYDANTOINS | HOFFMANN LA ROCHE (CH) | 2008-08-13 | — | — | EP | disclosed |
| US-20060041146-A1 | Substituted hydantoins | HOFFMANN-LA ROCHE AG | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041146-A1 | Substituted hydantoins | HNMT, MAPK6, KYNU | PTPN1 2154/4885PTPRC 2412/4885P2RX7 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.